Kirkland Advises SK Capital Partners on Acquisition of Apotex
Kirkland & Ellis advised an affiliate of funds advised by SK Capital Partners, LP (SK Capital), on its agreement to acquire Apotex Pharmaceutical Holdings Inc. (Apotex), a Canadian, global pharmaceutical company that produces high-quality, affordable generic medicines across all major therapeutic areas for patients around the world. Closing of the transaction is subject to the satisfaction of customary regulatory conditions.
Read the SK Capital press release
The Kirkland team was led by corporate partners Matthew Arenson, Peter Stach and Jeremy Liss and associates Justin Joffe, Rebecca Hart, Alexei Julian Segall and Constance Raftis, tax partners Benjamin Schreiner and Timothy Campany and associate Mike Shelton, debt finance partner Tom Dobleman and associates Lee Discher and Matthew Kita, derivatives partner Jaime Madell, rep and warranty insurance partner Hayley Hollender, employee benefits partner Jeffrey Quinn and associate Iris Grossman, executive compensation partners Michael Falk and Jake Ebers and associate Jenny Cha, labor and employment partners Evangelia Podaras and Paul Vasiloff, environmental transactions partners Jonathan Kidwell and Ty'Meka Reeves-Sobers and associate Kami Jones, real estate partner Joshua Faulkner and associates Kelly Bershader and Adam Amdur, technology & IP transactions partners Aaron Lorber and David MacDonald and associates Amy Barber, Bijan Motiwalla and Trevor Snider, healthcare regulatory partners Dennis Williams and Katie Sullivan and associates Dylan Mason and Kelly McGinnis, antitrust partners Thomas Wilson, Phillip Gnatzy, Carla Hine and Molly Kelley and associate Lucy Mahon, international trade and national security partner Mario Mancuso and associates Billy Phalen and Anais Bourbon, IP litigation partners Gianni Cutri, Jeanna Wacker and Chris Jagoe, litigation partners James Mutchnik, Martin Roth and Paul Sampson and associates Nick Ruge and Sarah Kimmer, and government contracts partner Robert Ryland.
